Growing evidence shows that the inhibition of ANO1 expression or activity can serve as therapeutic agents in NSCLC and include matrine [165], homoharringtonine (HHT), and arctigenin [163,164] (Figure 2). Here, ANO1 is linked to non-small cell lung carcinoma.